With a focus on the technology and life sciences industries, Emilio Ragosa counsels clients on securities offerings, mergers and acquisitions, and venture capital transactions. He also advises clients in corporate transactions ranging from seed financings, venture financings, and private placements to public offerings. Emilio’s clients include private and public companies, as well as venture capital firms and underwriters. By handling a range of transactions, Emilio is able to advise companies and investors across the business lifecycle. He currently serves as leader of the firm's Princeton office corporate business transactions practice.
Within the technology industry, Emilio has experience with digital media, financial services technology, e-commerce, and healthcare IT. Within the life sciences arena, his experience includes biotechnology, medical devices, and specialty pharmaceuticals.
Before entering private practice, Emilio gained experience with capital markets working at the New York Stock Exchange (NYSE) while in law school. He also interned with Merrill Lynch before attending law school.
Recently represented Agile Therapeutics with its recent IPO, and represented several other biotech companies in connection with their recent public offerings.
Represented a multinational specialty pharma company with its strategic investments in a US public company.
Represented a medical device company in a reverse merger, or now commonly referred to as an alternative public offering.
Represented many public biotech companies in connection with multiple PIPE deals and registered direct offerings.
Represented several funds in PIPEs and RDOs.
Represented underwriters in a specialty pharma IPO.
Mergers and Acquisitions
Recently represented Chiesi Farmaceutici, a private pharmaceutical company, with its acquisition of Cornerstone Therapeutics, a public specialty pharma company.
Represented a public biotech company in its sale to strategic buyer.
Represented a public company in its sale to private equity firm.
Represented a public clinical research organization in several private acquisitions of e-clinical companies.
Represented a public clinical research organization in a public tender offer of a public EDC company.
Represented many private tech and biotech companies in their critical sale transactions.
Represented many private tech and biotech companies with their successful angel and venture financings. Represented several venture capital firms and other funds with their investments in tech and biotech companies.
Represented pension funds with investments in private companies.
Rutgers University, 1995, B.S.
Rutgers University School of Law, Newark, 1998, J.D.
Awards and Affiliations
Recognized, Life Sciences Star: Finance and Transactional, LMG Life Sciences Guide (2016, 2017)
Recommended, M&A/Corporate and Commercial: Venture Capital and Emerging Companies, The Legal 500 US (2016, 2017)
Ranked, Chambers USA: America's Leading Lawyers for Business (2014–2017)
Recognized, 40 Under 40, New Jersey Law Journal (2010)
Frequent guest lecturer at Columbia University Entrepreneur Program
Member, Capital Markets Editorial Advisory Board, Law360 (2017)
Member, NJ Tech Council Board
Member, New York Venture Capital Association Board